Trial reportNature communications2023
Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis.
Open access · goldAbstract readRandomized Controlled TrialMulticenter Study
In one paragraph
Trial report in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 2 pooled it
13.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Biomarkers in ALS trials: from discovery to clinical utility.Frontiers in neuroscience · 2025Pooled it
- Efficacy and safety of pharmacological and biological therapies for amyotrophic lateral sclerosis: a network meta-analysis.Frontiers in neurologyPooled it
- Colchicine treatment in amyotrophic lateral sclerosis: safety, biological and clinical effects in a randomized clinical trial.Brain communications · 2024Trial
- Cell Death in Neurodegenerative Diseases: Molecular Mechanisms and Therapeutic Targets.MedComm · 2026Review
- Multivariate Survival Analysis of a Comprehensive Clinical Trial of Rapamycin in Amyotrophic Lateral Sclerosis Explores Prognostic Factors and Survival Patterns in C9orf72 Carriers.European journal of neurology · 2026Article
- Bridging the gap: neuroinflammation and the dawn of precision medicine in amyotrophic lateral sclerosis.Translational neurodegeneration · 2026Review
- Clinical significance of SQSTM1 variants in ALS: report of p.Arg119Cys and literature review.Neurogenetics · 2026Review
- The Role of Neurofilaments in Diagnosis and Monitoring of Amyotrophic Lateral Sclerosis.Journal of clinical medicine · 2026Review
- Agreement between bioimpedance-measured and calf-derived appendicular skeletal muscle mass in amyotrophic lateral sclerosis patients.European journal of clinical nutrition · 2026Article
- TDP-43 proteinopathy as a biomarker and therapeutic target in amyotrophic lateral sclerosis.Biochemical Society transactions · 2026Review
- Integrative analysis of drug-gene signatures in human pluripotent stem cells reveals prazosin as a novel SQSTM1 regulator for ALS therapeutics.Stem cell reports · 2026Article
- TDP-43 Aggregation: The Healthy-Toxic Balance of the Prion-Like Domain.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Regulatory T cells in cancer and inflammation.Signal transduction and targeted therapy · 2026Review
- Bench to bedside: is rapamycin headed for the docTOR?GeroScience · 2026Review
- Pharmacokinetic analysis of intermittent rapamycin administration in early-stage Alzheimer's Disease.GeroScience · 2026Article
- Isoginkgetin protects against degeneration of ALS motor neurons via regulating the GSK-3β-TFEB signaling axis.Pharmacological research · 2026Article
- Mechanism of action and clinical application of autophagy in multiple sclerosis (Review).International journal of molecular medicine · 2026Review
- Autophagy-Neuroinflammation Axis in Neurodegenerative Diseases: Mechanisms and Therapeutic Potential.Cells · 2026Review
- Immune imbalance between T helper 1, T helper 17 and regulatory T cells fuels amyotrophic lateral sclerosis pathogenesis: disease trajectory, diagnosis and therapeutic implications.Journal of neuroinflammation · 2026Review
- Grape Seed Proanthocyanins Extract Ameliorates the Neurotoxicity Induced by Fluoride Through mTOR/p70s6k Signaling Pathway in Vivo and in Vitro.Cell biochemistry and biophysics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 9 institutions in 1 country.
Jessica Mandrioli *Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy. jessica.mandrioli@unimore.it.ORCID http://orcid.org/0000-0002-9244-9782
Roberto D'AmicoUnit of Statistical and Methodological Support to Clinical Research, Azienda Ospedaliero-Universitaria, Modena, Italy.
Elisabetta Zucchi *Department of Neurosciences, St. Agostino-Estense Hospital, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
Sara De Biasi *Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy.
Federico Banchelli *Unit of Statistical and Methodological Support to Clinical Research, Azienda Ospedaliero-Universitaria, Modena, Italy.
Ilaria MartinelliDepartment of Neurosciences, St. Agostino-Estense Hospital, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
Cecilia SimoniniDepartment of Neurosciences, St. Agostino-Estense Hospital, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
Domenico Lo TartaroDepartment of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy.
Roberto ViciniUnit of Statistical and Methodological Support to Clinical Research, Azienda Ospedaliero-Universitaria, Modena, Italy.ORCID http://orcid.org/0000-0002-1799-6567
Nicola FiniDepartment of Neurosciences, St. Agostino-Estense Hospital, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
Giulia GianferrariDepartment of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.ORCID http://orcid.org/0000-0002-4260-0915
Marcello PintiDepartment of Life Sciences, University of Modena and Reggio Emilia, 41125, Modena, Italy.
Christian LunettaNEuroMuscular Omnicenter, Serena Onlus Foundation, Milan, Italy.
Francesca GerardiNEuroMuscular Omnicenter, Serena Onlus Foundation, Milan, Italy.
Claudia TarlariniNEuroMuscular Omnicenter, Serena Onlus Foundation, Milan, Italy.
Letizia MazziniALS Centre, Neurologic Clinic, Maggiore della Carità University Hospital, Novara, Italy.
Fabiola De MarchiALS Centre, Neurologic Clinic, Maggiore della Carità University Hospital, Novara, Italy.ORCID http://orcid.org/0000-0003-0197-1880
Ada ScognamiglioALS Centre, Neurologic Clinic, Maggiore della Carità University Hospital, Novara, Italy.
Gianni SorarùDepartment of Neurosciences, University of Padua, Padua, Italy.
Andrea FortunaDepartment of Neurosciences, University of Padua, Padua, Italy.
Giuseppe Lauria3rd Neurology Unit and ALS Centre, IRCCS 'Carlo Besta' Neurological Institute, Milan, Italy.
Eleonora Dalla Bella3rd Neurology Unit and ALS Centre, IRCCS 'Carlo Besta' Neurological Institute, Milan, Italy.
Claudia CaponnettoDepartment of Neurosciences, Rehabilitatioņ Ophthalmology, Genetics, Mother and Child Disease, Ospedale Policlinico San Martino, Genova, Italy.
Giuseppe MeoDepartment of Neurosciences, Rehabilitatioņ Ophthalmology, Genetics, Mother and Child Disease, Ospedale Policlinico San Martino, Genova, Italy.
Adriano Chio'Rita Levi Montalcini' Department of Neurosciences, ALS Centre, University of Turin and Azienda Ospedaliero Universitaria Città della Salute e della Scienza, Turin, Italy.
Andrea Calvo'Rita Levi Montalcini' Department of Neurosciences, ALS Centre, University of Turin and Azienda Ospedaliero Universitaria Città della Salute e della Scienza, Turin, Italy.ORCID http://orcid.org/0000-0002-5122-7243
Andrea CossarizzaDepartment of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy.ORCID http://orcid.org/0000-0002-5381-1558
University of Modena and Reggio Emilia · ITAssociazione Italiana Vulvodinia Onlus · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITAzienda Ospedaliero-Universitaria di Modena · ITAzienda Unita' Sanitaria Locale Di Modena · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITOspedale Policlinico San Martino · ITUniversity of Padua · ITIstituti Clinici Scientifici Maugeri · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
In preclinical studies rapamycin was found to target neuroinflammation, by expanding regulatory T cells, and affecting autophagy, two pillars of amyotrophic lateral sclerosis (ALS) pathogenesis. Herein we report a multicenter, randomized, double-blind trial, in 63 ALS patients who were randomly assigned in a 1:1:1 ratio to receive rapamycin 2 mg/m
Indexed as
Amyotrophic Lateral SclerosisAutophagyHumansInterleukin-18Quality of LifeRibosomal ProteinsInterleukin-18Ribosomal Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.